Home › NCT05850416

mGlide-Care: A Partnership With Caregivers

mGlide-Care: A Partnership With Caregivers to Improve HTN Management in Patients With Cognitive Impairment

Who can join

Ages 60 to 85 · All sexes

Inclusion Criteria: Must meet all criteria

* Diagnosed with early stage AD/ADRD or MCI
* Have uncontrolled hypertension (HTN)
* Have an unpaid, family caregiver
* Have established medical diagnosis of hypertension (HTN)
* English speaking
* Participant or caregiver must have a smartphone or mobile device (e.g. iPad) that can transmit blood pressure (BP) from the BP monitor
* Participant and caregiver capable and willing to comply with the entire study protocol
* Able to give voluntary written informed consent.

Exclusion Criteria: Any of the following will be an exclusion.

* Severe comorbid illness including end-stage kidney disease, end-stage liver disease, and life expectancy \<1 year, or if medical complexity of the patient precludes clinical trial participation
* Active illicit drug use (e.g. cocaine, methamphetamines, opioids, phencyclidine) since this will interfere with HTN management
* Participant and caregiver unable to complete study tasks, including are homeless, will leave the country, or will relocate in the next 12 months
* Serious psychiatric illness that could interfere with treatment, assessment, or compliance including significant delusional disorders such as schizophrenia and bipolar illness
* Unable or unwilling to give consent.

About the study

Hypertension (HTN) is the most significant stroke, cardiovascular disease and dementia risk factor and is substantially under-treated especially in older persons. In this study the investigators will develop mGlide-Care to address uncontrolled HTN in people with mild cognitive impairment (MCI) and early stage Alzheimer's Disease and Alzheimer's Disease Related Dementia (AD/ADRD). mGlide-Care is adapted from mGlide which is a mHealth (mobile health technology) mediated care model for HTN care. Aim 1 will engage stakeholders to study the acceptability of mHealth mediated HTN care and will use their input to develop mGlide-Care. Stakeholders are persons with early stage AD/ADRD and MCI, unpaid family caregivers, primary care providers, geriatricians and clinical pharmacists. Aim 2 is a feasibility pilot to test mGlide-Care vs. usual care in 75 participants with uncontrolled HTN and early stage AD/ADRD or MCI. Caregivers will assist participants. Outcomes will include HTN control and participant and caregiver reported measures.

What is being tested

• mGlide-Care (other)
• Usual Care + (other)

Sponsor: University of Minnesota · Participants: 75 · Started: Jan 15, 2026

Contact the study team

• Kamakshi Lakshminarayan · Phone: 6512085980

Official record on ClinicalTrials.gov — NCT05850416

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.